In Vitro Evaluation of Metabolic Drug-Drug Interactions: Concepts and Practice

Drug-Drug Interactions in Pharmaceutical Development

Volumn , Issue , 2007, Pages 1-29

  Li, Albert P ^a  

^a In Vitro ADMET Laboratories LLC   (United States)

Author keywords

Drug drug interactions; Drug metabolizing enzyme; Isoform specific inhibitors

Indexed keywords

EID: 84889483786     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470187920.ch1     Document Type: Chapter

References (53)

1. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmaol Ther 2002;72:685-691.
2. Barnes HJ, Arlotto MP, Waterman MR. Expression and enzymatic activity of recombinant cytohrome P450 17-alpha-hydroxylase in Esherichia coli. Proc Natl Acad Sci 1991;88:5597-5601.
3. Brown HS, Galetin A, Hallifax D, Houston B. Prediction of in vivo drug-drug interactions from in vivo data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 2006;45: 1035-1050.
4. Carlson AM, Morris LS. Coprescription of terfenadine and erythromycin or ketoconazole: an assessment of potential harm. J Am Pharm Assoc (Wash) 1996; NS36:263-269.
5. Capone D, Aiello C, Santoro GA, Gentile A, Stanziale P, D'Alessandro R, Imperatore P, Basile V. Drug interaction between cyclosporine and two antimirobial agents, josamycin and rifampicin, in organ-transplanted patients. Int J Clin Pharmacol Res 1996;16:73-76.
6. Chiba M, Jin L, Neway W, Vacca JP, Tata JR, Chapman K, Lin JH. Drug Metab Disp 2001;29:1-3.
7. Crespi CL. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 1995;26:179-235.
8. Diasio RB. Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br J Clin Pharma Col 1998;46:1-4.
9. Donato MT, Jimenez N, Castell JV, Gomez-Lechon J. Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metab Disp 2004;32:699-706.
10. Emoto C, Murase S, Sawada Y, Jones BC, Iwasaki K. In vitro inhibitory effects of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. Drug Metab Pharmacokinet 2003;18:287-295.
11. Friedberg T, Pritchard MP, Bandera M, Hanlon SP, Yao D, McLaughlin LA, Ding S, Burhell B, Wolf CR. Merits and limitations of recombinant models for the study of human P450-mediated drug metabolism and toxicity-an intralaboratory comparison. Drug Metab Rev 1999;31:523-544.
12. Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 2006;8:E101-E111.
13. Hariparsad N, Nallani S, Sane RS, Buckley DJ, Buckley AR, Desai PB. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmaol 2004;44:1273-1281.
14. Henderson L, Yue QY, Berqquist C, Gerden B, Arlett P. St. John's Wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002;54:349-356.
15. Hewitt NJ, Lechon MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Huillouzo A, Tuschi G, Li AP, Elcluyse E, Groothuis GM, Hengstler JG. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatoxicity studies. Drug Metab Rev 2007;39:159-234.
16. Huang SM, Lesko LJ, Williams RL. Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues. J Clin Pharmacol 1999;39:1006-1014.
17. Kato M, Tachibana T, Ito K, Sugiyama Y. Evaluation of methods for predicting drug-drug interactions by Monte Carlo simulation. Drug Metab Pharmacokinet 2003;18:121-127.
18. Kim JY, Baek M, Lee S, Kim SO, Dong MS, Kim BR, Kim DH. Characterization of the selectivity and mechanism of cytochrome P450 inhibition by dimethyl-4,40-dimethoxy-5,6,50,60-dimethylenedioxybiphenyl-2,20-dicarboxylate. Drug Metab Disp 2001;29:1555-1560.
19. Li AP. Scientific basis of drug-drug interactions: mechanism and preclinical evaluation. Drug Inform J 1988;32:657-664.
20. Li AP. Primary hepatocyte cultures as an in vitro experimental model for the evaluation of pharmacokinetic drug-drug interactions. Adv Pharmacol 1997;43:103-130.
21. Li AP. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov Today 2001;6:357-366.
22. Li AP. In vitro approaches to evaluate ADMET drug properties. Curr Top Med Chem 2004;4:701-706.
23. Li AP. Human hepatocytes: isolation, cryopreservation and applications in drug development. Chem Biol Interact 2007;168:16-29.
24. Li AP, Gorycki PD, Hengstler JG, Kedderis GL, Koebe HG, Rahmani R, de Sousas G, Silva JM, Skett P. Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. Chem Biol Interact 1999a;121:117-123.
25. Li AP, Hartman NR, Lu C, Collins JM, Strong JM. Effects of cytochrome P450 inducers on 17 alpha-ethinyloestradiol (EE2) conjugation by primary human hepatocytes. Br J Clin Pharmacol 1999;48:733-742.
26. Li AP, Lu C, Brent JA, Pham C, Fackett A, Ruegg CE, Silber PM. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem Biol Interact 1999b;121: 17-35.
27. Li AP, Maurel P, Gomez-Lechon MJ, Cheng LC, Jurima-Romet M. Applications of primary human hepatocytes in the evaluation of P450 induction. Chem Biol Interact 1997;107:5-16.
28. Li AP, Rasmussen A, Xu L, Kaminski DL. Rifampicin induction of lidocain metabolism in cultured human hepatocytes. J Pharmacol Exp Ther 1995;274: 673-677.
29. Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV, Lee CA. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Disp 1998;26:609-616.
30. Lu C, Miwa GT, Prakash SR, Gan LS, Balani SK. A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data, Drug Metab Disp 2007;35:79-85.
31. Lu AYH, Wang RW, Lin JH. Commentary: Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches for P450 isoform identification. Drug Metab Disp 2003;31:345-350.
32. MacGregor JT, Collins JM, Sugiyama Y, Tyson CA, Dean J, Smith L, Andersen M, Curren RD, Houston JB, Kadlubar FF, Kedderis GL, Krishnan K, Li AP, Parchment PE, Thummel K, Tomaszewski JE, Ulrich R, Vickers AE, Wrighton SA. In vitro human tissue models in risk assessment: report of a consensus-building workshop. Toxicol Sci 2001;59:17-36.
33. Madeira M, Levine M, Chang TKH, Mirfazaelian A, Bellward G. The effect of cimetidine on dexromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6. Drug Metab Disp 2004;32:460-467.
34. McGinnity DF, Berry AJ, Kenny JR, Grime K, Riley RJ. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Disp 2006;34:1291-1300.
35. Nelson AC, Huang W, Moody DE. Human liver microsome preparation: impact on the kinetics of L-a-acetylmethadol (LAAM) N-demethylation and dextromethorphan Odemethylation. Drug Metab Disp 2001;29:319-325.
36. Omar MA, Wilson JP. FDA adverse event reports on statin associated rhabdomyolysis. Ann Pharmacother 2002;36:288-295.
37. Ozdemir O, Boran M, Gokce V, Uzun Y, Kocak B, Korkmaz S. A case with severe rhabdomyolysis and renal failure associated with cerevastatin-gemfibrozil combination therapy-a case report. Angiology 2000;51:695-697.
38. Raucy J, Lasker JM. Isolation of P450 enzymes from human livers. Methods Enzymol 1991;206:577-594.
39. Renwick AB, Surry D, Price RJ, Lake BG, Evans DC. Metabolism of 7-benzyloxy-4-trifluoromethylcoumarin by human hepatic cytochrome P450 isoforms. Xenobiotica 2004;30:955-969.
40. Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of human cytochromes P450 responsible for atomozetine metabolism. Drug Metab Disp 2002;30:319-323.
41. Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 1999;57:465-480.
42. Roymans D, Annaert P, Van Houdt J, Weygers A, Noukens J, Sensenhauser C, Silva J, van Looveren C, Hendrickx J, Mannens G, Meuldermans W. Expression and induction potential of cytohromes P450 in human cryopreserved hepatocytes. Drug Metab Disp 2005;33:1004-1016.
43. Roymans D, Van Looveren C, Leone A, Parker JB, McMillan M, Johnson MD, Koganti A, Gilissen R, Silber P, Mannens G, Meuldermans W. Determination of cytochrome P450 1A2 and P450 3A4 induction in cryopreserved human hepatocytes. Biochem Pharmacol 2004;67:427-437.
44. Schalcher C, Schad K, Brunner-La Rocca HP, Schindler R, Oechslin E, Scharf C, Suetsch G, Bertel O, Kiowski W. Interaction of sildenafil with cAMP-mediated vasodilation in vivo. Hypertension 2002;40:763-767.
45. Uttamsingh V, Lu C, Miwa G, Gan LS. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Disp 2005;33:1723-1728.
46. Vazquez E, Whitfield L. Seldane warnings. Posit Aware 1997;8:12.
47. Vickers AE, Sinclair JR, Zollinger M, Heitz F, Glanzel U, Johanson L, Fischer V. Multiple cytochrome P450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos 1999;27: 1029-1038.
48. Von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relations to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 1996;16:104-112.
49. Vrtic F, Haefeli WE, Drewe J, Krahenbuhl S, Wenk M. Interaction of ibuprofen and probenecid with metabolizing enzyme phenotyping procedures using caffeine as the probe drug. Br J Clin Pharmacol 2003;55:191-198.
50. Walsh CT. Suicide substrates, mechanism-based enzyme inactivators: recent developments. Ann Rev Biochem 1984;53:493-535.
51. Wang RW, Newton DJ, Liu N, Atkins WM, Lu AYH. Human cytochrome P-450 3A4:in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Disp 2000;28:360-366.
52. Wen X, Wang JS, Backman JT, Kivisto KT, Neuvonen PJ. Gemfibrozil as an inhibitor of human cytochrome P450 2C9. Drug Metab Disp 2001;29:1359-1361.
53. Zhang H, Cui D, Wang B, Han YH, Balimane P, Yang Z, Sinz M, Rodriqus AD. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet 2007;46:133-157.